News
AU Press Releases



Alumna appointed CEO at firm specializing in implantable drug delivery devices
7/22/14

The board of directors of MicroCHIPS Inc., a developer of implantable drug delivery devices in Lexington, MA, has appointed Cheryl R. Blanchard Ph.D., a member of AU’s Class of 1986, as chief executive officer and member of the board, effective immediately.

Cheryl, who was formerly senior vice president and chief scientific officer at Zimmer Inc., Warsaw, IN, joins MicroCHIPS at a time when the company is preparing for the next stage of commercialization for its implantable drug delivery devices with a near-term focus on applications for women’s health.

“As the former chief scientific officer and general manager of the biologics business at a global medical device company Cheryl brings a skill set critical for MicroCHIPS to commercialize its products. Her past experiences in bringing complex medical products through the FDA and global regulatory authorities performing clinical trials and obtaining reimbursement as well as building the biologics business at Zimmer make her a great fit” said Richard Mott executive chairman of the board of MicroCHIPS.

Cheryl has extensive experience in the medical device and biologics sectors. For the past 12 years she served in roles of increasing responsibility at Zimmer, a medical device company focused on musculoskeletal products. Her roles at Zimmer included leadership of research and development clinical quality and regulatory affairs and health economics. She was also a member of Zimmer’s executive committee and developed and led the biologics business at Zimmer through disciplined execution of an R&D pipeline coupled with significant partnering and business development activities.

“I am thrilled to be joining MicroCHIPS to lead the company to the next stage of commercializing game-changing products in women’s health” said Cheryl. “A big part of my role will be to focus and build the company to commercialize products that address unmet needs for patients globally with this ground-breaking approach to delivering drugs.”

MicroCHIPS is currently developing its microchip-based implant to provide daily drug dosing ranging from six months to 16 years of therapy. The device can be programmed wirelessly allowing the physician to adjust the dosing for individual patient needs. It is implanted under the skin in a simple outpatient procedure using local anesthesia. MicroCHIPS is currently developing drug delivery devices in women's health applications for contraception and osteoporosis and in chronic diseases of multiple sclerosis and diabetes.